Clinical trials: Influenza Vaccines
Influenza
Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults
The aim of the study is to evaluate the safety and immunogenicity of the 2011-2012 formulation of Fluzone and Fluzone High-Dose vaccines in participants aged 65 years and older.
- Trial name
- NCT01430819
- Testing
- Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation, Influenza Virus Vaccine: Fluzone® High-Dose 2011-2012 Formulation
- Where
- 6 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Human
Clinical Performance Study of the Ultra Influenza A&B Test Using Nasal Swabs for Identifying Subjects Who Are Infected With the Influenza Virus Strain Type A or Type B
The clinical performance of the Ultra Influenza A\&B Test will be demonstrated during a clinical trial in which prospectively collected nasal swabs are used in identifying subjects who are infected with the influenza virus strain…
- Trial name
- NCT01753531
- Testing
- Flu Symptoms
- Where
- 3 sites in United States
- Volunteers
- 677 people
- Sponsor
- Sekisui Diagnostics, LLC
Influenza, Human
Phase 3 Pivotal Trial of NanoFlu™ in Older Adults
A Phase 3, randomized, observer-blinded, active-controlled trial to evaluate the immunogenicity and safety of a recombinant quadrivalent nanoparticle influenza vaccine with Matrix-M1 adjuvant (NanoFlu) compared with a licensed…
- Trial name
- NCT04120194
- Testing
- NanoFlu, Fluzone Quadrivalent
- Where
- 19 sites in United States
- Volunteers
- 2,654 people, healthy volunteers welcome
- Sponsor
- Novavax
H7N9 Influenza
Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP)
Study SP-1219-007 is a multi-centre, randomised, study designed to access the safety and tolerability of two doses of monovalent Influenza A (H7N9) vaccine delivered intradermally by a microarray patch delivery system in healthy…
- Trial name
- HD-MAP (NCT06417853)
- Testing
- Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Injection, Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA), Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA)
- Where
- 4 sites in Australia
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- Vaxxas Pty Ltd
Influenza
Phase 3 Immunogenicity and Safety Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)
The objectives of this study are to assess the immune response as well as the safety and tolerability of an H5N1 influenza vaccine in an adult and elderly population.
- Trial name
- NCT00462215
- Testing
- Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen
- Where
- 2 sites in Austria, Germany
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza
Rapid Diagnostic Test for Influenza
The primary objective of this study is to evaluate the performance of the MSD® Influenza Test in detecting influenza A and influenza B in subjects presenting with influenza-like-illness (ILI).
- Trial name
- NCT01089816
- Testing
- Local/Regional Public Health Notification
- Where
- 4 sites in Vietnam
- Volunteers
- 569 people
- Sponsor
- Meso Scale Diagnostics, LLC.
Influenza, Influenza A
A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus
The goal of this clinical study is to prove the no less immunogenicity of the Grippol Quadrivalent vaccine compared to the Grippol plus vaccine in children aged 6 months to 5 years (inclusive) for three identical strains of the…
- Conditions
- Influenza, Influenza A, Influenza, Human, Influenza Type B
- Trial name
- NCT06385821
- Testing
- Grippol Quadrivalent, Grippol Plus
- Where
- 14 sites in Russia
- Volunteers
- 824 people, healthy volunteers welcome
- Sponsor
- NPO Petrovax
Influenza
Study to Evaluate Immunogenicity & Safety of an Investigational Influenza Vaccine in Adults
The objective of this study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A.
- Trial name
- NCT00975884
- Testing
- GSK investigational vaccine GSK2340272A
- Where
- 5 sites in France
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Annual Study for Fluarix Registration
A pre-requisite to the yearly licensing process of the Influenza vaccine (FluarixTM/ Influsplit SSW®) is to demonstrate in clinical studies, the immunogenicity and reactogenicity of the vaccine composed of the new strains…
- Trial name
- NCT00306943
- Testing
- Influsplit SSW®
- Where
- 5 sites in Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers
This is a study to assess the immune (antibody) response and safety of a bioCSL split virion, inactivated influenza vaccine containing the 2013/2014 formulation of Enzira® vaccine in healthy adult volunteers aged between 18 and…
- Trial name
- NCT01863433
- Testing
- Trivalent Influenza Vaccine
- Where
- United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
A Study on Emergence of Resistance With Oseltamivir (Tamiflu) in Participants With Seasonal Influenza
This open-label randomized 2 arm study will determine the emergence of viral resistance in participants with seasonal influenza A infection treated with oseltamivir.
- Trial name
- NCT00949533
- Testing
- Oseltamivir
- Where
- 3 sites in Brazil
- Volunteers
- 37 people
- Sponsor
- Hoffmann-La Roche
Influenza
Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults
The aim of the study is describe the safety and immunogenicity of Fluzone Quadrivalent and Fluzone Intradermal vaccines in adults 18 to < 65 years of age, and to describe the safety and immunogenicity of Fluzone Quadrivalent and…
- Trial name
- NCT01946438
- Testing
- Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),, Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),, Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)
- Where
- 4 sites in United States
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID-19, Influenza A
Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel
The study is designed as a prospective, multicentric, clinical study to investigate the positive percent agreement (PPA) and negative percent agreement (NPA) of the Panbio™ COVID-19/Flu A\&B Panel using anterior nasal swab…
- Conditions
- COVID-19, Influenza A, Influenza B
- Trial name
- NCT06127108
- Testing
- Panbio™
- Where
- United States
- Volunteers
- 447 people
- Sponsor
- Abbott Rapid Dx
Human Influenza
Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above
The present study is designed to confirm the safety and immunogenicity of trivalent, surface antigen, inactivated influenza vaccine in 2 age cohorts: 18 to ≤60 years and ≥61 years and the antibody response to each influenza…
- Trial name
- NCT01885117
- Testing
- TIVf
- Where
- Germany
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
COVID-19, Diabetes Mellitus
Incidence of Diabetes After a COVID-19 Infection
Prospective observational study of the POINTED consortium to evaluate whether new diagnoses of diabetes mellitus, occur significantly more frequently in the post-acute phase of a laboratory-confirmed SARS-CoV-2 infection than in…
- Trial name
- POINTED_Diab (NCT05524792)
- Testing
- no interventional study
- Where
- Germany
- Volunteers
- 157,134 people
- Sponsor
- InGef - Institute for Applied Health Research Berlin GmbH
Covid19, RSV Infection
Sample Collection Study to Aid Evaluation of an Influenza A/B, Respiratory Syncytial Virus & COVID-19 Virus POC Test
Collection of Nasal Swabs, Throat Swabs and Saliva Samples from patients presenting at their designated care or testing facility displaying symptoms of either Influenza, Respiratory Syncytial Virus (RSV), SARS-CoV-2 or those who…
- Conditions
- Covid19, RSV Infection, Influenza Type A, Influenza Type B
- Trial name
- INFORM (NCT04782336)
- Testing
- Sample Collection
- Where
- 6 sites in United Kingdom
- Volunteers
- 79 people
- Sponsor
- LumiraDx UK Limited
Influenza, Respiratory Viral Infection
A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections
The main purpose of the study was to evaluate the effectiveness of XC221, tablets, at a dose of 200 mg/day compared to placebo in patients with uncomplicated influenza or other acute respiratory viral infections (ARIs).
- Trial name
- NCT05544916
- Testing
- XC221
- Where
- 13 sites in Russia
- Volunteers
- 260 people
- Sponsor
- Valenta Pharm JSC
Influenza
Study to Evaluate Immunological Equivalence Between Two Investigational Influenza Vaccines in Adults (H1N1)
The primary purpose of the study is to assess the equivalence of the immune response elicited by two GSK Biologicals' adjuvanted influenza investigational vaccines (GSK2340272A and GSK2340274A) in adults aged 18 to 60 years.
- Trial name
- NCT00979407
- Testing
- Influenza vaccine GSK2340272A, Influenza vaccine GSK2340274A
- Where
- 7 sites in France, Germany
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Virus Diseases
Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults
UMN-0501 is a purified recombinant influenza HA vaccine (A H5N1/Vietnam/1203/2004). The purpose of the present study is to evaluate immunogenicity, safety and optimal dose among three different doses of UMN-0501 following two…
- Trial name
- NCT00980447
- Testing
- UMN-0501
- Where
- 2 sites in Japan
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- UMN Pharma Inc.
Healthy
Safety and Tolerability of a Cell-Derived Influenza Vaccine in Healthy Adults Aged ≥18 Years and ≤ 49 Years
A controlled, double blinded study to determine the safety and reactogenicity in healthy adults of a single dose of a trivalent cell-derived influenza vaccine administered by intramuscular injection.
- Trial name
- NCT00599443
- Testing
- Seasonal cell-derived influenza vaccine
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Solvay Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.